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Objective To compare the cost-effectiveness of an additional
24-hour inpatient observation for asymptomatic term neonates
born to group B streptococcus (GBS) -colonised mothers with
adequate intrapartum antibiotic prophylaxis (IAP) after an initial
24-hour in-hospital observation.
Design Cost-effectiveness analysis from a societal perspective.
Setting United States.
Population Asymptomatic term neonates born to GBS-colonised
mothers with IAP after an initial 24-hour in-hospital observation.
Methods Monte Carlo simulation for a decision tree model
incorporating the following chance events: development of GBS
sepsis during the second 24 hours of life, development of GBS
sepsis between 48 hours and 7 days of life, prompt versus delayed
treatment for sepsis, neonatal mortality and long-term health
sequelae.
Main outcome measures Expected cost and quality-adjusted life
years (QALYs), Incremental cost-effectiveness ratio (ICER).
Results Delayed, versus early, hospital discharge results in similar
mean expected QALYs, but substantially higher expected cost.
The mean difference in QALY is 0.00016 (95% CI 0.00005–
0.00040), whereas the mean difference in cost is $1170.96 (95% CI
$750.13–1584.32). The ICER is estimated to be $9,771,520.87 per
QALY (95% CI $2,573,139.89–24,407,017.82). The proportion of
early-onset GBS that develops during the second 24 hours of life,
the cost of 24 hours of inpatient observation, and the probability
of long-term sequelae following prompt versus delayed treatment
play important roles in determining the cost-effectiveness of
delayed hospital discharge.
Conclusion Cost-effectiveness analysis suggests that with adequate
IAP, discharging asymptomatic term neonates to home after
24 hours is the preferred approach compared with 48 hours
inpatient observation.
Keywords Healthcare costs, patient discharge, postpartum period,
sepsis, Streptococcus agalactiae.
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Introduction
Sepsis caused by Streptococcus agalactiae, commonly
referred to as Group B Streptococci (GBS), has historically
been one of the leading causes of neonatal morbidity and
mortality in the USA.1 Neonatal GBS sepsis occurring
before the 7th day of life is referred to as early-onset GBS
(EOGBS) sepsis;2 in the past, this accounted for the major-
ity of cases. Although improvements in newborn care have
led to better outcomes for neonates that develop EOGBS
sepsis, the disease remains associated with short-term and
long-term morbidities and mortality, including asymptom-
atic bacteraemia, pneumonia, meningitis, prolonged hospi-
talisation, need for ventilatory support, hearing and vision
impairment, and mental retardation.3,4 The Centers for
Disease Control and Prevention (CDC), the American Col-
lege of Obstetricians and Gynecologists, and the American
Academy of Pediatrics (AAP) therefore set a goal to iden-
tify means to prevent the development of GBS sepsis.1
As research in the latter half of the twentieth century
revealed that intrapartum antibiotic prophylaxis (IAP) pro-
vided to mothers in labour could prevent the development
of EOGBS sepsis in the newborn,5 these same three organi-
sations released guidelines in 1996, subsequently revised in
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2002, and recently updated in 2010, outlining screening
and treatment recommendations designed to reduce the
incidence of EOGBS sepsis. The CDC now recommends
screening all pregnant women for GBS colonisation
between 35 and 37 weeks of gestation, and providing IAP
treatment for all colonised women or women whose colo-
nisation status is unknown but who have identified risk
factors.6 Implementation of these policies has been remark-
ably effective, reducing the incidence of EOGBS sepsis from
1.5 to 2 cases per 1000 live births to approximately 0.3
cases per 1000 live births.6–8
Despite the success of IAP, there continues to be uncer-
tainty over the length of time that neonates born to women
known to be colonised by GBS should be observed after
birth. The CDC and AAP both recommend that neonatal
observation be continued for 48 hours.6,7,9 However, they
also concede that neonates that appear healthy and that are
born to women appropriately treated with IAP (defined as
administration of antibiotics ‡4 hours before delivery of
the infant6) may be discharged after 24 hours if they can be
effectively observed at home.6,7,10 At many institutions,
however, neonates born to GBS-colonised women are
observed for longer than 24 hours, regardless of whether
adequate IAP was provided.11 This necessitates an extra
night’s stay for the neonate (and typically the mother as
well), incurring higher costs, delayed return to the comforts
of home, and increased risk of nosocomial infections.
As approximately 10–30% of all pregnant women in the
USA have been shown to be colonised with GBS,7 many
mothers and infants (both in the USA and in other coun-
tries that have adopted the screening approach advocated
by the CDC) are currently experiencing delayed hospital
discharge under the standard protocols. Given the impor-
tance of cost considerations in national and international
health policy making, we undertook a cost-effectiveness
analysis of delayed hospital discharge (defined as discharge
after an additional 24 hours of in-hospital observation) for
term, asymptomatic neonates who are born to women col-
onised with GBS and treated with adequate IAP.
Methods
Decision tree model
Patients in this analysis were defined as term infants who
were asymptomatic at 24 hours of life but were born via
vaginal delivery to women with known GBS colonisation
who received adequate IAP. We constructed a decision tree
model to compare two discharge approaches: (i) discharge
at 24 hours and (ii) discharge at 48 hours, i.e. an addi-
tional 24-hour inpatient observation period before dis-
charge. The model is illustrated in Figure 1, which starts at
24 hours after birth with an asymptomatic newborn. The
decision node represents the two discharge approaches, and
the branches following each discharge approach reflect the
subsequent health events. These health events include
development of GBS sepsis during the second 24 hours
after birth, development of GBS sepsis 48 hours after birth
but within 7 days of birth, delayed or prompt treatment
for EOGBS sepsis, and resultant health outcomes (death,
live infant with long-term sequelae, or live infant with no
long-term sequelae). For each of these health events, the
model considers its probability of happening and the asso-
ciated costs and health-related quality of life. The time-
frame of our analysis starts from the second 24 hours of
life throughout the lifetime of the newborn. Hence the
model allows us to estimate the expected outcomes of each
discharge approach and compare them.
Data sources
Estimates of all input parameters for the decision tree
model, including estimates of the probability, cost and util-
ity associated with each health state, were obtained from a
comprehensive literature review. In developing parameter
estimates related to the probabilities of health events, two
authors (MBB and ELM) searched the English-language lit-
erature from 1 January 1993 to 5 November 2009 using the
databases Medline, Pubmed and EMbase and search terms
‘group B streptococcus’ or ‘agalactiae’ and ‘neonatal’. We
identified 1740 abstracts from which we retrieved 45 full-
text articles. The search was subsequently updated on 14
October 2011. In all, 538 titles or abstracts were identified,
from which we retrieved 21 full-text articles. We supple-
mented our search with review of the reference lists of rele-
vant publications. From a final 28 full-text articles deemed
appropriate for our study population and research ques-
tion, along with national reports, we derived estimates of
the value and plausible ranges for all probability, cost and
utility data associated with each of the health events in the
model (Table 1).12–47
Effectiveness was measured using quality-adjusted life-
years (QALYs). For an individual person, QALY is com-
puted by multiplying the number of expected life-years in
each health state by the ‘utility’ associated with that health
state and then summing across the health states. A utility
score provides a quantification of an average person’s pref-
erence for being in a particular health state. It is a continu-
ous measure with values ranging from 0 to 1, with 0
representing death and 1 representing perfect health. A
health state less than perfect health but better than death
would take a value between 0 and 1. Because of the lack of
estimates for the utility scores of long-term sequelae of
EOGBS sepsis, we used the corresponding values for indi-
viduals with cerebral palsy as an approximation.42,43
Likewise, annual cost and life expectancy associated with
individuals manifesting sequelae of EOGBS sepsis were
approximated using the corresponding values for individuals
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with cerebral palsy.37,41 For individuals who never devel-
oped EOGBS sepsis or who were successfully treated for
EOGBS sepsis, i.e. without long-term sequelae, we adjusted
each additional surviving year of their life with the age-spe-
cific health-related quality of life for the average US popu-
lation.47 This is to account for the fact that people could
suffer from other diseases throughout their lifespan and
hence have less than perfect health in subsequent life years.
Data sources used for probability and cost estimates were
assessed for their level of evidence by two authors (MBB
and ELM) (Table 1). The sources were independently
assessed by the two authors using the Oxford Centre for
Evidence-based Medicine—Levels of Evidence (March
2009) and consensus on a final score was determined
through discussion.
We conducted the analysis from a societal perspective. All
cost estimates were adjusted to 2010 US dollars.48 Cost and
QALY estimates later in life were discounted to the time at
birth using a 3% discount rate with sensitivity analyses con-
ducted using a 0% and 5% discount rate, respectively.
Data analysis
As recommended by the Panel on Cost Effectiveness in
Health and Medicine, we performed a multivariate sensitiv-
ity analysis using Monte Carlo simulation.49 In Monte Car-
lo simulation, possible values of each input parameter in
the model were defined by a prespecified distribution. Dur-
ing each iteration of the simulation, a random value of
each input parameter was drawn from such prespecified
distributions, which forms one set of parameter values. The
Figure 1. Decision tree model. The decision analysis begins after the first 24 hour in-hospital observation period has been completed and the
newborn is asymptomatic at that time; no costs or sequelae associated with the first 24-hour inpatient observation are included in the model. Filled
square indicates a decision node, filled circle indicates a chance event, and filled triangle indicates an end node of a branch. Tx = treatment.
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Table 1. Parameter estimates for the model
Parameter
Most
likely value Minimum Maximum Reference
Level of
evidence
Among term neonates born to women known to be colonised by GBS
but who received adequate IAP, the probability that EOGBS sepsis
develops during the first 24 hours*
0.0396% 0.0210% 0.0450% 12–16 2b, 2b, 2b,
5, 2b
Among all newborns with EOGBS sepsis, the proportion that develop
symptoms during the first 24 hours of life*
89.0% 61.0% 95.0% 17–24 2b, 2b, 2b, 1a,
4, 1a, 1a, 2b
Among all newborns with EOGBS sepsis, the proportion that develop
symptoms during the second 24 hours*
5.0% 3.0% 32% 17, 20, 22,
25, 26
2b, 1a, 1a,
4, 2c
Probability of delayed treatment for newborns that develop EOGBS
sepsis while under hospital observation
1.0% 0.0% 5.0% 18 2b
Probability of delayed treatment for newborns that develop EOGBS
sepsis while not under hospital observation
100% – – Authors’
assumption
5
Probability of death among newborns with EOGBS sepsis and delayed
treatment
10.0% 8.0% 12.0% 27–29 2b, 5, 5
Probability of having long-term sequelae among newborns with EOGBS
sepsis and delayed treatment
30.0% 20.0% 40.0% 27 2b
Probability of death among newborns with EOGBS sepsis and prompt
treatment
3.0% 1.0% 5.0% 27–30 2b, 5, 5, 2b
Probability of having long-term sequelae among newborns with EOGBS
sepsis and prompt treatment
14.0% 2.0% 26.0% 27, 28, 30 2b, 5, 2b
Cost of an additional 24-hour hospital observation $1,182 $591 $1,773 31, 32 2b, 2c
Cost of an emergency department visit for newborns developing
EOGBS sepsis while not under inpatient observation
$341 $171 $512 33, 34 2c, 2c
Cost of EOGBS sepsis treatment $23,021 $17,662 $95,102 31, 34–36 2b, 2c, 2c, 1b
Lifetime cost of long-term sequelae resulting from EOGBS sepsis** $1,018,465 $509,232 $1,527,697 37 2c
Usual weekly earnings of US workers*** $747 $290 $1,769 38 2c
Life expectancy at birth for newborns without EOGBS sepsis or with
successfully treated EOGBS sepsis
77.90 – – 40 2c
Life expectancy at birth for newborns with long-term sequelae
resulting from EOGBS sepsis**
42.70 11.20 67.70 41 2c
Utility weight of health state with long-term sequelae resulting from
EOGBS sepsis**
0.40 0.13 0.56 42, 43 2b, 2b
Utility weight of EOGBS sepsis health state**** 0.92 0.66 0.93 44, 47 2c
Duration of EOGBS sepsis symptoms (days) 8.80 0.00 34.20 45, 46 2b, 2b
Age-specific utility weights for the average US population 47 2c
0–5 0.94 – –
5–15 0.93 – –
15–20 0.92 – –
20–30 0.91 – –
30–35 0.90 – –
35–40 0.89 – –
40–45 0.88 – –
45–50 0.86 – –
50–55 0.83 – –
55–60 0.81 – –
60–65 0.77 – –
65–70 0.76 – –
70–75 0.74 – –
75–80 0.70 – –
EOGBS, early-onset group B streptococci; GBS, group B streptococci; IAP, intrapartum antibiotic prophylaxis.
All cost estimates reflect inflation against 2010 US dollars.
*These parameters were used to derive the probability of developing EOGBS sepsis during the second 24 hours of life (conditional on surviving the first
24 hours without EOGBS sepsis) and the probability of developing EOGBS sepsis after 48 hours of birth but within 7 days of birth (conditional on surviving
the first 48 hours of life without EOGBS sepsis).
**Approximated using data from individuals with cerebral palsy.
***This reflects the 90th centile of usual weekly earnings and was accounted for as such in the simulation.
****Approximated using the utility of need for admission to neonatal nursery.
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model is then run for this simulated parameter set and the
outcome measures are therefore calculated. This process is
repeated many times to account for the uncertainty of
parameter values. In our analysis, we performed Monte
Carlo simulation with 5000 iterations.
For each of the probability, utility and cost parameters
in our model, we assumed a PERT (Program Evaluation
and Review Technique) distribution, which is a special
form of the beta distribution and specifies minimum, max-
imum and most likely values as its distribution parameters
(Table 1).50 With 5000 iterations of data, the mean and
95% confidence intervals (95% CIs) for the expected cost
and QALY associated with early and delayed hospital dis-
charge, respectively, were calculated. Because our model
starts at 24 hours after birth with an asymptomatic new-
born, the estimated cost and QALY reflect the values start-
ing from the second 24 hours of life throughout the
lifetime of the newborn. We also estimated the mean and
95% CIs for the expected incremental cost, incremental
QALY, and the incremental cost-effectiveness ratio (ICER),
i.e. incremental cost divided by incremental QALY. A cost-
effectiveness plane and cost-effectiveness acceptability curve
were also constructed to assess the probability distribution
of the ICER.
Because estimates of cost, QALY, ICER and probability
of adverse outcomes are not normally distributed in our
simulation data, we estimated their 95% CIs based on a
non-parametric method using the 2.5th and 97.5th cen-
tiles.51 Debate is ongoing regarding whether to include pro-
ductivity cost in the numerator of the ICER,52–55 so we
included costs associated with productivity loss in primary
analysis, but performed a sensitivity analysis excluding such
costs. DecisionTools Suite software (Palisade Corpora-
tion, Ithaca, NY, USA) and SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA) were used for data analysis.
Results
Our analysis suggests that an additional 24-hour inpatient
observation results in slightly higher expected QALY as
compared with discharge at 24 hours of life (27.72054
versus 27.72038) (Table 2). This is because the longer in-
hospital observation increases the likelihood of providing
prompt treatment for EOGBS sepsis, hence reducing the
probability of neonatal death and adverse long-term
health sequelae. However, the mean expected cost of
delayed discharge, i.e. $1198.93, is approximately 43-fold
higher than that of early hospital discharge, i.e. $27.98.
To assess whether the expected QALYs differ significantly
between the two discharge strategies, we draw on the esti-
mated 95% CIs of the expected difference in QALY (and
likewise for expected cost). This is because within each
iteration of the simulation, the estimated QALYs for the
two discharge strategies were based on the same set of
parameter values drawn and hence, were not independent
from each other (and, likewise, for the estimated costs
associated with the two discharge strategies). The 95% CI
for the expected difference in cost and QALY suggest that
both were statistically significant. However, delayed hospi-
tal discharge, in an attempt to improve neonatal out-
comes, is associated with substantial additional costs
($1170.96 with 95% CI $750.13–1584.32) while resulting
in minimal QALY gain (0.00016 with 95% CI 0.00005–
0.00040). The mean ICER, or the additional cost to soci-
ety to gain one extra QALY, is $9,771,520.87 (95% CI:
$2,573,139.89 to $24,407,017.82).
Our model also suggests that delayed hospital discharge
has minimal effects not only on the expected QALYs but
on clinically relevant health outcomes as well. For example,
with delayed hospital discharge, the expected probability
that the newborn would die from EOGBS sepsis is
0.00043%. By contrast, the expected probability that the
newborn would die from EOGBS sepsis following early
hospital discharge is 0.00066%, with the expected difference
being 0.00023% (95% CI 0.00008–0.00054%) between the
two strategies. Likewise, the probability that the newborn
would have long-term health sequelae is 0.00146% and
0.00198%, respectively, following delayed and early hospital
discharge, with the difference being 0.00052% (95% CI
0.00011–0.00141%).
Table 2. Summary of simulation results
Delayed hospital discharge Early hospital discharge
Expected cost (US$) $1198.93 ($776.25–1614.38) $27.98 ($8.94–64.75)
Expected QALY 27.72054 (27.71991–27.72083) 27.72038 (27.71969–27.72074)
Expected difference in cost $1170.96 ($750.13–1584.32)
Expected difference in QALY 0.00016 (0.00005–0.00040)
Incremental cost-effectiveness ratio $9,771,520.87 ($2,573,139.89–24,407,017.82)
Data are reported as mean (95% confidence interval). The expected cost and QALYs reflect the values starting from the second 24 hours of life
throughout the lifetime of the newborn.
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The results of 5000 iterations of our simulation analysis
are shown in a cost-effectiveness plane (Figure 2). This fig-
ure plots the joint distribution of the incremental cost and
incremental QALY when comparing discharge after an
additional 24 hours of in-hospital observation with dis-
charge at 24 hours after birth. Each dot on the plane corre-
sponds to one incremental cost and QALY pair resulting
from one iteration of the simulation. All 5000 incremental
cost and QALY pairs fall within the northeast quadrant of
the cost-effectiveness plane, indicating a trade-off between
the cost and the QALY. That is, delayed hospital discharge
results in higher QALYs than early hospital discharge, but
is also more costly than early hospital discharge. Figure 2
illustrates significant variability in the magnitude of the
ICER.
To further evaluate the probability distribution of the
ICER, we generated a cost-effectiveness acceptability curve
(Figure 3). This curve reflects the probability that the addi-
tional 24-hour inpatient observation is cost-effective com-
pared with early discharge at different levels of ceiling
acceptable cost-effectiveness ratios. The ceiling acceptable
cost-effectiveness ratio indicates the maximum amount that
society would be willing to pay to gain one extra QALY.
For each given ceiling acceptable cost-effectiveness ratio, we
calculated the proportion of simulations in our analysis in
which the expected ICER was lower than that ratio. This
proportion estimates the probability that an additional 24-
hour inpatient observation is a more cost-effective strategy
than discharge at 24 hours after birth. The minimum ICER
generated in our simulation (n = 5000 iterations) was
$1,294,000.93 per QALY, which is more than 25-fold
greater than the commonly used maximum acceptable
cost-effectiveness ratio of $50,000 per QALY.56 Although
there has been debate regarding the appropriate dollar
value per QALY gained upon which to base resource allo-
cation decisions, the ICER estimates found in our analysis
do not suggest that an additional 24 hours of inpatient
observation is a cost-effective approach even when using
other, more lenient, estimates of cost per QALY (e.g.
$100,000/QALY).56
Our simulation data suggest that the most important fac-
tors influencing the cost-effectiveness of the additional
24 hours of inpatient observation include: the proportion of
EOGBS sepsis that develops during the second 24 hours of
life, the cost of 24 hours of inpatient observation, and the
probability of having long-term health sequelae following
prompt versus delayed GBS treatment. In addition, sensitiv-
ity analyses excluding costs for lost productivity generated
similar findings in terms of the overall cost-effectiveness of
delayed hospital discharge (mean ICER = $9,725,642.82;
95% CI $2,739,790.40–23,726,212.41; data not shown in
table). Varied discount rates (0% and 5%) did not affect
the key findings either.
Discussion
In this study, we compared the cost-effectiveness of two
hospital discharge approaches for term neonates who are
asymptomatic at 24 hours after birth and were born via
vaginal delivery to women colonised by GBS but treated
with adequate IAP: discharge at 24 hours after birth versus
discharge after an additional 24-hour inpatient observation.
The results suggest that discharging these infants after
an additional 24-hour inpatient observation is not a
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cost-effective approach, resulting in an estimated ICER
much higher than the conventionally accepted cost-effec-
tiveness thresholds.
It has been well documented that approximately 90% of
neonates with EOGBS sepsis develop symptoms within the
first 24 hours of life.17,18,21,22,24 In addition, it has been
demonstrated that physical examination is more sensitive
than various laboratory studies for identifying neonates
with sepsis,16 suggesting that newborns can be effectively
monitored at home. It is therefore interesting that the
recently revised CDC guidelines still recommend 48 hours
of inpatient observation for ‘well-appearing infants…whose
mother received adequate intrapartum GBS prophylaxis’.6
It should be noted that these updated guidelines continue
to indicate that 24 hours of in-hospital observation may be
sufficient, provided that ready access to medical care is
available and a person will be present who can comply with
instructions for home observation.
The CDC guidelines for GBS screening and prophylaxis
have resulted in remarkable improvements in the rates of
EOGBS sepsis, but have not strongly addressed their impact
on healthcare costs. In fact, the newest revision of the
guidelines highlights the need for further studies of the
effect of the guidelines on healthcare resource utilisation
and their influence on neonatal management strategies.6
Therefore, our study is an important addition to the cur-
rent literature on EOGBS sepsis as the existing GBS cost-
effectiveness studies have focused on the costs and benefits
of screening and treatment,30,31,57 rather than discharge
strategies after the baby is born.
Cost-effectiveness analyses, such as the one presented in
this study, have a marked potential to affect healthcare pol-
icy. The costs, risks and benefits of any strategy must there-
fore be considered in the context of existing legislation
governing related practices. The Newborns’ and Mothers’
Health Protection Act of 1996 (and, similarly, statutes
enacted by a majority of states in the USA) states that the
hospital stay after a vaginal delivery cannot be restricted to
less than 48 hours. This law does not, however, mandate
that women must stay in the hospital for 2 days postpar-
tum; rather, it is designated to regulate the minimum bene-
fits covered by health-insurance providers. Indeed, a recent
Policy Statement from the AAP’s Committee on Fetus and
Newborn explicitly acknowledges that discharge <48 hours
after delivery may be appropriate.58
These results must also be interpreted in the context of
prior experience with early hospital discharge of neonates.
In both private pay and Medicaid populations, large time-
series analyses of the effects of passage of length-of-stay
laws have been shown to result in similar health outcomes,
with similar rates of re-hospitalisation for all causes.59–61 A
recent Cochrane review of this subject similarly showed
that although there is significant heterogeneity in studies
comparing early and delayed discharge, maternal and neo-
natal outcomes appear to be similar under both strate-
gies.62
The large magnitude of the ICER estimate and its wide
confidence interval found in our study are primarily the
result of the relatively large difference in expected costs in
conjunction with the minimal difference in health out-
comes expected from the two discharge approaches. This
results in large estimates of the numerator with quite small
estimates of the denominator for the ICER. Variations in
the denominator across the 5000 iterations of the simula-
tion led to large changes in the ICER estimates. However,
even the minimum ICER calculated by our model, i.e.
$1,294,000.93, is substantially higher than the commonly
accepted cost-effectiveness threshold value of $50,000–
100,000 per QALY.56,63
Whether to include productivity cost in the numerator
of the ICER has been controversial.52–55 The Panel on Cost
Effectiveness in Health and Medicine recommended in
1996 that the monetary value of lost productivity should
not be included in the numerator of the ICER to avoid
double counting.49 This recommendation was based on an
assumption that respondents always take lost income into
consideration when evaluating the impact of a health state
on their quality of life. However, none of the existing
health-related quality of life instruments that are used to
estimate utility weights and hence, QALYs, explicitly ask
about forgone income or wages.55 A recent literature review
further demonstrated that without explicit instructions on
consideration of income, only a minority of respondents
actually include the effects of income losses in health state
valuation.54 Moreover, as argued by Meltzer and Johannes-
son,64 the assumption that people incorporate personal
financial consequences such as income losses into health-
state evaluations implies that they would also incorporate
other consequences such as out-of-pocket medical expenses
related to the health state, which may result in another type
of double counting as medical care costs of related diseases
is already included in the numerator.
Due to these considerations, we included productivity
costs in our primary analysis, but ran a sensitivity analysis
excluding such costs. There is no meaningful difference in
our conclusion. Indeed, because hospital discharge at
24 hours of life is associated with a greater probability of
neonatal death and long-term adverse health sequelae
because of delayed treatment of EOGBS sepsis, disregarding
productivity costs associated with premature death and lost
work time for those with long-term health sequelae would
change the results more in favour of early hospital dis-
charge. As our primary analysis already suggests that early
hospital discharge is the more cost-effective approach,
exclusion of productivity cost should not affect this conclu-
sion.
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The primary strength of this study is that it compares a
common practice that is in place for the purpose of pro-
tecting against the long-term, devastating and potentially
expensive sequelae of EOGBS sepsis with a standard that
has been emerging for many other healthcare and preven-
tion strategies.65 By attempting to frame this intervention
in this capacity, society can compare the cost-effectiveness
across different healthcare interventions to optimise alloca-
tion of our resources.
Fargason et al.57 have performed an analysis of paediatric
costs associated with the management of infants born to
GBS-positive mothers who received adequate intrapartum
prophylaxis after either a risk-based or culture-based
approach. Their study found that costs of paediatric care
constituted a large fraction of the cost per sepsis case
averted, although the degree to which paediatric observa-
tion may prevent or attenuate EOGBS disease is not estab-
lished. The authors note that in their cost analysis, the
length of neonatal observation significantly influences the
cost of sepsis prevention; however they did not explicitly
compare early versus delayed hospital discharge.57 In the
current study, we demonstrate that compared with early
discharge, delayed hospital discharge of healthy-appearing
term neonates born to colonised mothers who receive ade-
quate IAP is not cost-effective. Given that approximately
10–30% of all pregnant women in the USA have been
shown to be colonised with GBS,7 guidelines surrounding
the appropriate length of inpatient observation for neonates
born to women known to be colonised by GBS but with
adequate IAP have substantial cost implications.
Several limitations of the study should be acknowledged.
First, all modelling studies require simplification, and sev-
eral assumptions must be made because of lack of data.
For example, we assumed that under the early hospital dis-
charge strategy, all neonates with EOGBS sepsis symptoms
developed after the first 24 hours would receive delayed
treatment. This may be an oversimplification of real life
when some neonates may still be able to get prompt treat-
ment. However, relaxing this assumption should not
change our conclusion as more lenient assumptions would
further strengthen the case in favour of the early discharge
strategy. Second, there is a lack of data on the utility and
medical cost of individuals with long-term sequelae follow-
ing EOGBS sepsis. Hence, we used the estimates for per-
sons with cerebral palsy as an approximation. Third, the
estimates for the cost, utility and probability parameters in
our model are based on published literature. No primary
data collection was performed for this study; therefore
some parameter estimates may have a relatively wide range.
However, we conducted substantial sensitivity analysis to
assure the robustness of our findings. Finally, our parame-
ters on treatment pattern and incidence of health sequelae
were based on best data available in published literature up
to October 2011; these estimates might change in the
future as more accurate diagnostic tools and more effective
treatments become available.
Conclusion
Intrapartum antibiotic prophylaxis of GBS-colonised moth-
ers has greatly reduced the incidence of early onset GBS
sepsis in the USA and elsewhere. Our cost-effectiveness
analysis suggests that in the setting of having provided ade-
quate IAP, discharging healthy-appearing term neonates
born to GBS-colonised mothers after 24 hours is the pre-
ferred approach compared with 48 hours of inpatient
observation. Our findings, along with other data in the lit-
erature, also suggest that safety and cost-effectiveness
depend on timely identification and treatment of GBS dis-
ease in the neonate. Future research focusing on tools for
early identification of neonates at risk for developing GBS
sepsis before the development of symptoms will be useful.
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